Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Wim Trypsteen is active.

Publication


Featured researches published by Wim Trypsteen.


Analytical and Bioanalytical Chemistry | 2015

ddpcRquant: threshold determination for single channel droplet digital PCR experiments

Wim Trypsteen; Matthijs Vynck; Jan De Neve; Pawel Bonczkowski; Maja Kiselinova; Eva Malatinkova; Karen Vervisch; Olivier Thas; Linos Vandekerckhove; Ward De Spiegelaere

Digital PCR is rapidly gaining interest in the field of molecular biology for absolute quantification of nucleic acids. However, the first generation of platforms still needs careful validation and requires a specific methodology for data analysis to distinguish negative from positive signals by defining a threshold value. The currently described methods to assess droplet digital PCR (ddPCR) are based on an underlying assumption that the fluorescent signal of droplets is normally distributed. We show that this normality assumption does not likely hold true for most ddPCR runs, resulting in an erroneous threshold. We suggest a methodology that does not make any assumptions about the distribution of the fluorescence readouts. A threshold is estimated by modelling the extreme values in the negative droplet population using extreme value theory. Furthermore, the method takes shifts in baseline fluorescence between samples into account. An R implementation of our method is available, allowing automated threshold determination for absolute ddPCR quantification using a single fluorescent reporter.


Clinical Infectious Diseases | 2017

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection

Line Vibholm; Mariane H. Schleimann; Jesper F Højen; Thomas Benfield; Rasmus Offersen; Katrine Rasmussen; Anders Dige; Jørgen Agnholt; Judith Grau; Maria J. Buzon; Burghardt Wittig; Mathias Lichterfeld; Andreas Petersen; Xutao Deng; Mohamed Abdel-Mohsen; Satish K. Pillai; Sofie Rutsaert; Wim Trypsteen; Ward De Spiegelaere; Linos Vandekerchove; Lars Østergaard; Thomas A. Rasmussen; Paul W. Denton; Martin Tolstrup; Ole S. Søgaard

Background. Treatment with latency reversing agents (LRAs) enhances human immunodeficiency virus type 1 (HIV-1) transcription in vivo but leads to only modest reductions in the size of the reservoir, possibly due to insufficient immune-mediated elimination of infected cells. We hypothesized that a single drug molecule-a novel Toll-like receptor 9 (TLR9) agonist, MGN1703-could function as an enhancer of innate immunity and an LRA in vivo. Methods. We conducted a single-arm, open-label study in which 15 virologically suppressed HIV-1-infected individuals on antiretroviral therapy received 60 mg MGN1703 subcutaneously twice weekly for 4 weeks. We characterized plasmacytoid dendritic cell, natural killer (NK), and T-cell activation using flow cytometry on baseline and after 4 weeks of treatment. HIV-1 transcription was quantified by measuring plasma HIV-1 RNA during MGN1703 administration. Results. In accordance with the cell type-specific expression of TLR9, MGN1703 treatment led to pronounced activation of plasmacytoid dendritic cells and substantial increases in plasma interferon-α2 levels (P < .0001). Consistently, transcription of interferon-stimulated genes (eg, OAS1, ISG15, Mx1; each P < .0001) were upregulated in CD4+ T cells as demonstrated by RNA sequencing. Further, proportions of activated cytotoxic NK cells and CD8+ T cells increased significantly during MGN1703 dosing, suggesting an enhancement of cellular immune responses. In 6 of 15 participants, plasma HIV-1 RNA increased from <20 copies/mL to >1500 copies/mL (range, 21-1571 copies/mL) during treatment. Conclusions. TLR9 agonist treatment in HIV infection has a dual potential by increasing HIV-1 transcription and enhancing cytotoxic NK cell activation, both of which are key outcomes in HIV-1 eradication therapy. Clinical Trials Registration. NCT02443935.


Molecular Diagnosis & Therapy | 2016

The Future of Digital Polymerase Chain Reaction in Virology

Matthijs Vynck; Wim Trypsteen; Olivier Thas; Linos Vandekerckhove; Ward De Spiegelaere

Driven by its potential benefits over currently available methods, and the recent development of commercial platforms, digital polymerase chain reaction (dPCR) has received increasing attention in virology research and diagnostics as a tool for the quantification of nucleic acids. The current technologies are more precise and accurate, but may not be much more sensitive, compared with quantitative PCR (qPCR) applications. The most promising applications with the current technology are the analysis of mutated sequences, such as emerging drug-resistant mutations. Guided by the recent literature, this review focuses on three aspects that demonstrate the potential of dPCR for virology researchers and clinicians: the applications of dPCR within both virology research and clinical virology, the benefits of the technique over the currently used real-time qPCR, and the importance and availability of specific data analysis approaches for dPCR. Comments are provided on current drawbacks and often overlooked pitfalls that need further attention to allow widespread implementation of dPCR as an accurate and precise tool within the field of virology.


PLOS ONE | 2015

Comparison of methods for in-house screening of HLA-B∗57:01 to prevent abacavir hypersensitivity in HIV-1 care

Ward De Spiegelaere; Jan Philippé; Karen Vervisch; Chris Verhofstede; Eva Malatinkova; Maja Kiselinova; Wim Trypsteen; Pawel Bonczkowski; Dirk Vogelaers; Steven Callens; Jean-Louis Ruelle; Kabamba Kabeya; Stéphane De Wit; Petra Van Acker; Vicky Van Sandt; Marie Paule Emonds; Paul Coucke; Erica Sermijn; Linos Vandekerckhove

Abacavir is a nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy in HIV-1-infected patients. Because this drug can cause a hypersensitivity reaction that is correlated with the presence of the HLA-B*57:01 allotype, screening for the presence of HLA-B*57:01 is recommended before abacavir initiation. Different genetic assays have been developed for HLA-B*57:01 screening, each with specific sensitivity, turnaround time and assay costs. Here, a new real-time PCR (qPCR) based analysis is described and compared to sequence specific primer PCR with capillary electrophoresis (SSP PCR CE) on 149 patient-derived samples, using sequence specific oligonucleotide hybridization combined with high resolution SSP PCR as gold standard. In addition to these PCR based methods, a complementary approach was developed using flow cytometry with an HLA-B17 specific monoclonal antibody as a pre-screening assay to diminish the number of samples for genetic testing. All three assays had a maximum sensitivity of >99. However, differences in specificity were recorded, i.e. 84.3%, 97.2% and >99% for flow cytometry, qPCR and SSP PCR CE respectively. Our data indicate that the most specific and sensitive of the compared methods is the SSP PCR CE. Flow cytometry pre-screening can substantially decrease the number of genetic tests for HLA-B*57:01 typing in a clinical setting.


Scientific Reports | 2016

Differential expression of lncRNAs during the HIV replication cycle: an underestimated layer in the HIV-host interplay

Wim Trypsteen; Pejman Mohammadi; Clarissa Van Hecke; Pieter Mestdagh; Steve Lefever; Yvan Saeys; Pieter De Bleser; Jo Vandesompele; Angela Ciuffi; Linos Vandekerckhove; Ward De Spiegelaere

Studying the effects of HIV infection on the host transcriptome has typically focused on protein-coding genes. However, recent advances in the field of RNA sequencing revealed that long non-coding RNAs (lncRNAs) add an extensive additional layer to the cell’s molecular network. Here, we performed transcriptome profiling throughout a primary HIV infection in vitro to investigate lncRNA expression at the different HIV replication cycle processes (reverse transcription, integration and particle production). Subsequently, guilt-by-association, transcription factor and co-expression analysis were performed to infer biological roles for the lncRNAs identified in the HIV-host interplay. Many lncRNAs were suggested to play a role in mechanisms relying on proteasomal and ubiquitination pathways, apoptosis, DNA damage responses and cell cycle regulation. Through transcription factor binding analysis, we found that lncRNAs display a distinct transcriptional regulation profile as compared to protein coding mRNAs, suggesting that mRNAs and lncRNAs are independently modulated. In addition, we identified five differentially expressed lncRNA-mRNA pairs with mRNA involvement in HIV pathogenesis with possible cis regulatory lncRNAs that control nearby mRNA expression and function. Altogether, the present study demonstrates that lncRNAs add a new dimension to the HIV-host interplay and should be further investigated as they may represent targets for controlling HIV replication.


Retrovirology | 2018

Digital PCR as a tool to measure HIV persistence

Sofie Rutsaert; Kobus Bosman; Wim Trypsteen; Monique Nijhuis; Linos Vandekerckhove

Although antiretroviral therapy is able to suppress HIV replication in infected patients, the virus persists and rebounds when treatment is stopped. In order to find a cure that can eradicate the latent reservoir, one must be able to quantify the persisting virus. Traditionally, HIV persistence studies have used real-time PCR (qPCR) to measure the viral reservoir represented by HIV DNA and RNA. Most recently, digital PCR is gaining popularity as a novel approach to nucleic acid quantification as it allows for absolute target quantification. Various commercial digital PCR platforms are nowadays available that implement the principle of digital PCR, of which Bio-Rad’s QX200 ddPCR is currently the most used platform in HIV research. Quantification of HIV by digital PCR is proving to be a valuable improvement over qPCR as it is argued to have a higher robustness to mismatches between the primers-probe set and heterogeneous HIV, and forfeits the need for a standard curve, both of which are known to complicate reliable quantification. However, currently available digital PCR platforms occasionally struggle with unexplained false-positive partitions, and reliable segregation between positive and negative droplets remains disputed. Future developments and advancements of the digital PCR technology are promising to aid in the accurate quantification and characterization of the persistent HIV reservoir.


Retrovirology | 2014

Replication competent virus as an important source of bias in HIV latency models utilizing single round viral constructs

Pawel Bonczkowski; Ward De Spiegelaere; Alberto Bosque; Cory H. White; Anouk Van Nuffel; Eva Malatinkova; Maja Kiselinova; Wim Trypsteen; Wojciech Witkowski; Jolien Vermeire; Bruno Verhasselt; Laura J. Martins; Christopher H. Woelk; Vicente Planelles; Linos Vandekerckhove

The central memory T cell (TCM) model forms a unique HIV-1 latency model based on primary cells that closely resemble in vivo TCM. The virus employed in this model is based on an engineered vector incapable of replication after initial infection. We show that despite this strategy, replication competent viral particles are released into the culture medium due to recombination between overlapping sequences of the env deleted HIV genome that is co-transfected with intact env. This finding emphasizes the need for careful data analysis and interpretation if similar constructs are employed and urges for additional caution during laboratory work.


Journal of the International AIDS Society | 2014

Accurate episomal HIV 2-LTR circles quantification using optimized DNA isolation and droplet digital PCR

Eva Malatinkova; Maja Kiselinova; Pawel Bonczkowski; Wim Trypsteen; Peter Messiaen; Jolien Vermeire; Bruno Verhasselt; Karen Vervisch; Linos Vandekerckhove; Ward De Spiegelaere

In HIV‐infected patients on combination antiretroviral therapy (cART), the detection of episomal HIV 2‐LTR circles is a potential marker for ongoing viral replication. Quantification of 2‐LTR circles is based on quantitative PCR or more recently on digital PCR assessment, but is hampered due to its low abundance. Sample pre‐PCR processing is a critical step for 2‐LTR circles quantification, which has not yet been sufficiently evaluated in patient derived samples.


Scientific Reports | 2016

HIV-1 Vpr N-terminal tagging affects alternative splicing of the viral genome

Ann Baeyens; Evelien Naessens; Anouk Van Nuffel; Karin E. Weening; Anne-Marie Reilly; Eva Claeys; Wim Trypsteen; Linos Vandekerckhove; Sven Eyckerman; Kris Gevaert; Bruno Verhasselt

To facilitate studies on Vpr function in replicating HIV-1, we aimed to tag the protein in an infectious virus. First we showed that N-, but not C-terminal HA/FLAG tagging of Vpr protein preserves Vpr cytopathicity. Cloning the tags into proviral DNA however ablated viral production and replication. By construction of additional viral variants we could show this defect was not protein- but RNA-dependent and sequence specific, and characterized by oversplicing of the genomic RNA. Simulation of genomic RNA folding suggested that introduction of the tag sequence induced an alternative folding structure in a region enriched in splice sites and splicing regulatory sequences. In silico predictions identified the HA/His6-Vpr tagging in HIV-1 to affect mRNA folding less than HA/FLAG-Vpr tagging. In vitro infectivity and mRNA splice pattern improved but did not reach wild-type values. Thus, sequence-specific insertions may interfere with mRNA splicing, possibly due to altered RNA folding. Our results point to the complexity of viral RNA genome sequence interactions. This should be taken into consideration when designing viral manipulation strategies, for both research as for biological interventions.


Biomolecular Detection and Quantification | 2017

Evaluation of relative quantification of alternatively spliced transcripts using droplet digital PCR

Mattias Van Heetvelde; Wouter Van Loocke; Wim Trypsteen; Annelot Baert; Katrien Vanderheyden; Brecht Crombez; Jo Vandesompele; Kim De Leeneer; Kathleen Claes

Introduction For the relative quantification of isoform expression, RT-qPCR has been the gold standard for over a decade. More recently, digital PCR is becoming widely implemented, as it is promised to be more accurate, sensitive and less affected by inhibitors, without the need for standard curves. In this study we evaluated RT-qPCR versus RT-droplet digital PCR (ddPCR) for the relative quantification of isoforms in controls and carriers of the splice site mutation BRCA1 c.212+3A>G, associated with increased expression of several isoforms. Materials and methods RNA was extracted from EBV cell lines of controls and heterozygous BRCA1 c.212+3A>G carriers. Transcript-specific plasmids were available to determine the efficiency, precision, reproducibility and accuracy of each method. Results Both ddPCR and RT-qPCR were able to accurately quantify all targets and showed the same LOB, LOD and LOQ; also precision and reproducibility were similar. Both techniques have the same dynamic range and linearity at biologically relevant template concentrations. However, a significantly higher cost and workload was required for ddPCR experiments. Conclusions Our study recognizes the potential and validity of digital PCR but shows the value of a highly optimized qPCR for the relative quantification of isoforms. Cost efficiency and simplicity turned out to be better for RT-qPCR.

Collaboration


Dive into the Wim Trypsteen's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Maja Kiselinova

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Karen Vervisch

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge